TIANYUN HAN^#, ZHONG LI^#, LUONING ZHANG, LINSHEN XIE^*

BIOCELL, Vol.48, No.11, pp. 1625-1638, 2024, DOI:10.32604/biocell.2024.055029 - 07 November 2024

Abstract Objective: The study aimed to explore the protective mechanism of Ganoderic acid A (GAA) in renal fibrosis and to verify that GAA can ameliorate renal fibrosis by regulating the Niemann-pick C1-like 1 (NPC1L1) gene. Methods: Transforming growth factor beta1 (TGF-β1) was used to treat Human Kidney-2 (HK-2) cells to establish a renal fibrosis model. The differentially expressed genes in the control (CTRL) group, TGF-β1 group, and TGF-β1 + GAA group were screened via transcriptome sequencing technology and verified by qPCR and Western blot experiments. The NPC1L1 gene overexpression plasmid was constructed. The expression levels of N-cad, E-cad,… More >

YAN LI¹, HUZHI CAI², XIAOLING PENG³, YOUHUI LIU⁴, QINGYANG CHEN⁴, XIANGDONG LIN⁵, XINYU CHEN^6,*

BIOCELL, Vol.48, No.3, pp. 501-511, 2024, DOI:10.32604/biocell.2023.030854 - 15 March 2024

Abstract Background: Renal fibrosis is an important process in the development of chronic kidney disease. Understanding the pathogenesis and finding effective treatments for renal fibrosis is crucial. This study aims to investigate whether a newly discovered long non-coding RNA (lncRNA) called LOC103694972 could be a potential target for treating fibrosis of NRK-49F cells. Methods:: LncRNA Chip was used to identify differentially expressed lncRNAs between TGF-β1-induced NRK-49F cells and normal cells. The dual-luciferase assay confirmed the binding between miR-29c-3p and signal transducer and activator of transcription (STAT3), as well as between miR-29c-3p and lncRNA LOC103694972. Si-LOC103694972 and… More > Graphic Abstract

GIULIA CHIABOTTO^1,*, STEFANIA BRUNO^2,*

BIOCELL, Vol.47, No.7, pp. 1499-1508, 2023, DOI:10.32604/biocell.2023.028121 - 21 June 2023

Abstract Renal fibrosis and inflammation are common pathological features of chronic kidney disease (CKD). Since currently available treatments can only delay the progression of CKD, the outcome of patients with CKD is still poor. One therapeutic option for the prevention of CKD-related complications could be the use of mesenchymal stromal cells (MSCs), which have shown beneficial effects in tissue fibrosis and regeneration after damage. However, safety issues, such as cellular rejection and carcinogenicity, limit their clinical application. Among the bioactive factors secreted by MSCs, extracellular vesicles (EVs) have shown the same beneficial effect of MSCs, without More > Graphic Abstract